NOW APPROVED IN FL1:
KYMRIAH® (tisagenlecleucel) is indicated for the treatment of adult patients with relapsed or refractory follicular lymphoma (FL) after two or more lines of systemic therapy.
FL
DLBCL1
I Am KYMRIAH

Because

I want to empower my own immune system to fight DLBCL
I need a CAR-T treatment with proven efficacy and a manageable safety profile
I refuse to give up hope

DLBCL
ALL1
I Am KYMRIAH

Because

I want to empower my own immune system to fight ALL
I want a CAR-T treatment with the potential to put my ALL in remission
I have lots of living left to do

ALL
Images throughout do not depict actual KYMRIAH patients.
Reference:
  • 1.Kymriah Summary of Product Characteristics. Novartis Pharma AG; 2022.

You are now leaving KYMRIAH.com and will be redirected to Novartis.com to review the press release.

Cancel
Continue